Lance Faddis, MD
Internal Medicine · Centerton, ARNPI 1255398400
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,586 and has fallen 56.8% since, to $686 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$768
- GSK$764
- Lilly USA, LLC$544
- Amgen$520
- AstraZeneca$518
- Novo Nordisk$318
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,829100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $768 |
| GSK | 63 | $764 |
| Lilly USA, LLC | 37 | $544 |
| Amgen(2 entities) | 29 | $520 |
| AstraZeneca | 34 | $518 |
| Novo Nordisk | 19 | $318 |
| Merck | 26 | $315 |
| Pfizer | 20 | $251 |
| Boehringer Ingelheim | 14 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $151 |
| Bayer | 8 | $149 |
| Supernus Pharmaceuticals, Inc. | 8 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $128 |
| Astellas Pharma US Inc | 8 | $117 |
| Johnson & Johnson | 7 | $90 |
| Genentech USA, Inc. | 5 | $88 |
| Exact Sciences | 5 | $86 |
| Abbott | 5 | $83 |
| Dynavax Technologies Corporation | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $76 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $36 |
| Alfasigma USA, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$5,837 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $56,530 |
| JardianceEmpagliflozin | 28 | $39,479 |
| XareltoRivaroxaban | 22 | $20,890 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $17,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,989 |
| FarxigaDapagliflozin Propanediol | 17 | $11,658 |
| EliquisApixaban | 19 | $11,122 |
| Dofetilide | 12 | $3,123 |
| Atorvastatin Calcium | 193 | $1,508 |
| Pregabalin | 55 | $1,408 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $1,265 |
| Rosuvastatin Calcium | 109 | $1,102 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,095 |
| Gabapentin | 50 | $976 |
| Levothyroxine Sodium | 78 | $875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $233 | $57,35746 claims |
| Novo NordiskOzempic | $318 | $56,53037 claims |
| Johnson & JohnsonXarelto | $90 | $20,89022 claims |
| GSKTrelegy Ellipta | $764 | $13,98922 claims |
| AstraZenecaFarxiga | $518 | $11,65817 claims |
| PfizerEliquis | $251 | $11,12219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Centerton
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Stuart BensonRogers$24K
- Purnima SarkarEarle$21K
- John NorwoodJonesboro$21K
- Ahmed AliConway$18K
- Jeremy DavisLittle Rock$17K
- Tyree SealsFort Smith$14K
- Atif KhanBatesville$14K
- Ritesh RampureLittle Rock$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.